HUTCHMED (China) Ltd
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
other
SEC Category
Large accelerated filer
State of Incorporation
Cayman Islands
Country
Hong Kong
Business Address
48TH FLOOR, CHEUNG KONG CENTER, HONG KONG, ,
Mailing Address
48TH FLOOR, CHEUNG KONG CENTER, HONG KONG, ,
Phone
852-2121-3888
EIN
000000000
Financial Overview
FY2025
$1.75B
Total Assets
$0.53
EPS
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 6-K Foreign company current report | April 9, 2026 | View on SEC |
| 6-K Foreign company current report | April 9, 2026 | View on SEC |
| 3 Initial insider ownership report | March 31, 2026 | View on SEC |
| 6-K Foreign company current report | March 23, 2026 | View on SEC |
| 3 Initial insider ownership report | March 18, 2026 | View on SEC |
| 6-K Foreign company current report | March 16, 2026 | View on SEC |
| 3 Initial insider ownership report | March 16, 2026 | View on SEC |
| 3 Initial insider ownership report | March 11, 2026 | View on SEC |
| 6-K Foreign company current report | March 11, 2026 | View on SEC |
| 3 Initial insider ownership report | March 10, 2026 | View on SEC |
Annual Reports
20-F
March 5, 2026
- HUTCHMED achieved a robust 25% increase in total revenue, reaching $550 million, driven by strong product sales.
- The U.S. FDA approved SULANDA (fruquintinib) for metastatic colorectal cancer, marking a pivotal global expansion.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.